VolitionRx Limited (NYSEAMERICAN:VNRX) Short Interest Up 23.6% in November

VolitionRx Limited (NYSEAMERICAN:VNRX) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 546,400 shares, a growth of 23.6% from the October 31st total of 441,900 shares. Based on an average daily volume of 123,400 shares, the days-to-cover ratio is currently 4.4 days.

VolitionRx Trading Down 5.9 %

NYSEAMERICAN VNRX traded down $0.04 during trading on Monday, hitting $0.65. The company had a trading volume of 385,188 shares, compared to its average volume of 163,437. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The firm has a market capitalization of $41.04 million, a PE ratio of -1.16 and a beta of 1.59.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.